Total Payments
$5,966
2024 Payments
$427.30
Companies
32
Transactions
289
Medicare Patients
11,440
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$5,767 (96.7%)
Education$199.31 (3.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,767 | 285 | 96.7% |
| Education | $199.31 | 4 | 3.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $896.22 | 51 | $0 (2024) |
| Amgen Inc. | $640.72 | 26 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $622.76 | 39 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $542.45 | 29 | $0 (2024) |
| PFIZER INC. | $484.57 | 26 | $0 (2024) |
| Abbott Laboratories | $338.47 | 11 | $0 (2024) |
| Merck Sharp & Dohme LLC | $268.70 | 12 | $0 (2023) |
| Astellas Pharma US Inc | $252.79 | 6 | $0 (2020) |
| Philips Electronics North America Corporation | $226.51 | 5 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $224.51 | 14 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $427.30 | 22 | Novartis Pharmaceuticals Corporation ($143.83) |
| 2023 | $698.11 | 32 | Amgen Inc. ($97.11) |
| 2022 | $953.35 | 36 | Philips Electronics North America Corporation ($205.08) |
| 2021 | $793.66 | 39 | PFIZER INC. ($185.35) |
| 2020 | $328.77 | 16 | Novartis Pharmaceuticals Corporation ($87.82) |
| 2019 | $896.24 | 49 | Astellas Pharma US Inc ($199.50) |
| 2018 | $919.00 | 46 | Janssen Pharmaceuticals, Inc ($225.75) |
| 2017 | $949.40 | 49 | Amgen Inc. ($222.71) |
All Payment Transactions
289 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Boston Scientific Corporation | LUX-Dx Insertable Cardiac Monitor (Device) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: LUX-Dx_CRM | ||||||
| 12/06/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $9.06 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $31.29 | General |
| Category: Cardiovascular | ||||||
| 11/18/2024 | Abbott Laboratories | MITRACLIP (Device) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: Vascular | ||||||
| 11/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: Cardio-renal | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Cardiology | ||||||
| 09/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/09/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: Cardio-renal | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $22.18 | General |
| Category: Cardiovascular | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: Cardio-renal | ||||||
| 07/02/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $1.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/26/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Cardiology | ||||||
| 04/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $29.06 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: Cardio-renal | ||||||
| 03/07/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/12/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/05/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $26.18 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/15/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: Cardiology | ||||||
| 12/01/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/02/2023 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 3,116 | 4,484 | $738,677 | $294,009 |
| 2022 | 28 | 2,937 | 4,415 | $779,108 | $315,083 |
| 2021 | 29 | 2,940 | 4,442 | $806,430 | $327,477 |
| 2020 | 27 | 2,447 | 3,756 | $611,608 | $232,533 |
Total Patients
11,440
Total Services
17,097
Medicare Billing
$1.2M
Procedure Codes
124
All Medicare Procedures & Services
124 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 453 | 813 | $175,608 | $79,633 | 45.3% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 48 | 48 | $72,288 | $37,524 | 51.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 54 | 54 | $49,950 | $17,938 | 35.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 103 | 104 | $47,320 | $17,436 | 36.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 99 | 99 | $40,590 | $16,383 | 40.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 140 | 190 | $27,740 | $14,181 | 51.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 83 | 213 | $33,256 | $13,881 | 41.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 210 | 222 | $32,622 | $12,563 | 38.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 558 | 981 | $39,240 | $11,470 | 29.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 82 | 82 | $23,780 | $11,273 | 47.4% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 38 | 152 | $24,320 | $6,771 | 27.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 41 | $16,839 | $5,798 | 34.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 42 | 58 | $12,216 | $5,685 | 46.5% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 27 | 27 | $13,932 | $5,598 | 40.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 558 | 694 | $15,637 | $4,609 | 29.5% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 27 | 27 | $14,661 | $4,459 | 30.4% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 20 | 25 | $14,025 | $4,030 | 28.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 20 | 20 | $11,532 | $3,469 | 30.1% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 47 | 71 | $5,845 | $3,433 | 58.7% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Facility | 2023 | 109 | 111 | $8,098 | $2,972 | 36.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 53 | 53 | $9,964 | $2,854 | 28.6% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 54 | 108 | $22,680 | $2,523 | 11.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 48 | $4,182 | $1,947 | 46.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $4,563 | $1,390 | 30.5% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 28 | 28 | $3,220 | $1,271 | 39.5% |
About Dr. Thomas Diggs, M.D
Dr. Thomas Diggs, M.D is a Cardiovascular Disease healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962418889.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Diggs, M.D has received a total of $5,966 in payments from pharmaceutical and medical device companies, with $427.30 received in 2024. These payments were reported across 289 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($5,767).
As a Medicare-enrolled provider, Diggs has provided services to 11,440 Medicare beneficiaries, totaling 17,097 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 124 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location San Diego, CA
- Active Since 07/31/2006
- Last Updated 02/14/2011
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1962418889
Products in Payments
- ENTRESTO (Drug) $768.13
- ELIQUIS (Drug) $767.68
- XARELTO (Drug) $622.76
- Repatha (Biological) $470.62
- VERQUVO (Drug) $248.53
- LifeVest (Device) $216.78
- MITRACLIP (Device) $213.04
- BRILINTA (Drug) $206.25
- Barostim Neo System (Device) $194.65
- Corlanor (Drug) $170.10
- CAMZYOS (Drug) $161.38
- PRALUENT (Drug) $151.74
- (5044) MCOT (Device) $146.96
- LEQVIO (Drug) $128.09
- PRALUENT ALIROCUMAB INJECTION (Biological) $109.22
- Kerendia (Drug) $81.16
- (5055) Healthcare Und (Device) $79.55
- LEXISCAN (Drug) $76.80
- UPTRAVI (Drug) $70.56
- VYNDAQEL (Drug) $69.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in San Diego
Jonathan Hsu, Md, MD
Cardiovascular Disease — Payments: $1.1M
Cardiovascular Disease $1.1M
Dr. Raghava Gollapudi, M.d, M.D
Cardiovascular Disease — Payments: $572,162
Cardiovascular Disease $572,162
Dr. Hirsch Mehta, Md, MD
Cardiovascular Disease — Payments: $527,825
Cardiovascular Disease $527,825
Dr. Barry Greenberg, M.d, M.D
Cardiovascular Disease — Payments: $463,770
Cardiovascular Disease $463,770
Dr. Mitul Patel, M.d, M.D
Cardiovascular Disease — Payments: $459,569
Cardiovascular Disease $459,569
Dr. Ulrika Birgersdotter-Green, Md, MD
Cardiovascular Disease — Payments: $430,713
Cardiovascular Disease $430,713